Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances, whereby Vicore Pharma receives gross proceeds of SEK 500 million.
The share issuances were directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is conditional upon approval by an extraordinary general meeting and that a prospectus is published. Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).
Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.
